A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UK

Positioning of cabozantinib in the treatment pathway (second line, third line, fourth line or above)

Distribution, mean (SD) and median (quartiles) cabozantinib starting dose.

Mean (SD) and median (quartiles) cabozantinib daily dose during treatment.

Proportion of patients with dose modifications and mean (SD) and median (quartiles) number of dose modifications per patient.

Radiation procedures, denosumab, bisphosphonates.

Mean (SD) and median (quartiles) time (months

Metastatic sites (lung / liver / bone / lymph node / brain / visceral other) documented co-morbidities and distribution of relevant co-morbidities.

Distribution of IMDC risk group (favourable, intermediate, poor). From patient's medical records (if documented) or calculated from the individual components (haemoglobin, Karnofsky Performance Status, time from advanced RCC diagnosis to systemic treatment initiation, calcium, neutrophils, platelets).

PFS is defined as the time from cabozantinib initiation until the date of first documented evidence of disease progression or death from any cause. Disease progression is defined as either radiological disease progression (according to RECIST criteria [if documented in routine practice] or other local investigator assessment]) or clinical progression

OS will be measured from both cabozantinib initiation (time from cabozantinib initiation until death from any cause) and from advanced RCC diagnosis (from advanced RCC diagnosis until death from any cause).

ORR defined as the proportion of patients achieving a complete or partial response